Medicover Posts 8% Organic Growth in Q3 as €740 Million India Hospital Sale to KKR Nears November Close

Sweden-headquartered healthcare and diagnostics operator Medicover AB announced its third-quarter 2026 financial results on November 4, 2026, delivering solid organic expansion alongside confirmation that the sale of its Indian hospital operations to funds managed by global investment firm KKR is on track to close by late November.

The presentation revealed that Medicover’s continuing operations grew organic revenue by 8.0% year-on-year to €570.8 million, while operating profit (EBIT) surged 22.0% to €49.3 million. The quarter marked the company's seventh consecutive period of year-on-year operating margin expansion, improving to 8.6% from 7.5% in Q3 2025.

The Landmark €1.2 Billion India Exit

The strategic centrepiece of Medicover's corporate reshaping is the outright divestment of Medicover Hospitals India (MHI) to KKR. Originally agreed in August 2026, the deal values the Indian hospital entity at an enterprise valuation of €1.2 billion (approximately ₹13,188 crore).

Medicover holds a 66.1% controlling stake in MHI, with the remaining 33.9% held by local founding partners. From this transaction, Medicover expects gross cash proceeds of approximately €740 million, an amount that includes €100 million from the settlement of shareholder loans and accrued interest.

Key Transaction and Footprint Highlights:

• Valuation Benchmark: The transaction values the business at €1.2 billion on an enterprise value basis, representing one of the largest foreign sponsor buyouts in Indian hospital delivery.
• Network Size: Medicover Hospitals India runs 24 multi-specialty hospitals with approximately 4,700 to 4,800 operational beds across key non-metro and tier-1 clusters in Telangana, Andhra Pradesh, Maharashtra, and Karnataka.
• Revenue Contribution: MHI generated trailing twelve-month revenues of €220.5 million as of June 30, 2026, accounting for approximately 10% of Medicover's consolidated top line prior to its reclassification as a discontinued operation.
• Timeline: Medicover management reiterated that all regulatory milestones are progressing smoothly, with deal completion expected no later than the end of November 2026.

Q3 2026 Earnings Performance ex-India

Following the reclassification of the Indian hospital arm as discontinued operations, Medicover's remaining businesses—centred predominantly in Poland, Germany, and Romania—delivered broad-based operational gains.

Reported revenues rose 6.0% to €570.8 million, with organic revenue rising 8.0% after absorbing a 2.0% foreign currency translation headwind. Adjusted EBITDA advanced 7.1% to €101.3 million, translating to a margin of 17.8%. Net profit from continuing operations improved to €24.8 million compared to €19.2 million in the year-ago period, while group total net profit reached €25.2 million.

The impending capital influx from the Indian divestment has already begun de-risking Medicover's capital structure. Group leverage moderated to 2.7x net debt to adjusted EBITDA, well within its corporate ceiling of 3.0x. John Stubbington, Chief Executive Officer of Medicover, noted that exiting India will allow the company to operate as a lean, highly focused provider across its three core European markets with greater financial flexibility.

Strategic Implications for the Indian Hospital Market

For domestic market watchers, Medicover's exit provides crucial signals regarding asset valuations, capital allocation strategies, and private equity appetite in Indian healthcare:

1. Private Equity Consolidation Accelerates KKR’s buyout of Medicover Hospitals India reinforces the buyout major’s aggressive aggregation strategy in the domestic medical delivery space. KKR previously acquired a controlling stake in Kerala-based Baby Memorial Hospital and holds an influential position in Bengaluru-based oncology specialist HealthCare Global Enterprises (HCG). By taking control of Medicover's substantial network across South and Western India, KKR creates a potent platform capable of competing directly with domestic heavyweights such as Apollo Hospitals, Manipal Hospitals, and Fortis Healthcare.

2. Premium Valuations Overriding IPO Routes Before sealing the transaction with KKR, Medicover had spent months preparing for a domestic initial public offering (IPO) of its Indian unit. However, the willingness of global private equity sponsors to pay premium EBITDA multiples—reportedly in the mid-40s range—prompted the European parent to choose an immediate, debt-clearing cash exit rather than navigate listing volatility and lock-in requirements.

3. Heightened Focus on Regional Dominance Medicover’s Indian network gained critical mass not through pan-India tier-1 city bidding wars, but by establishing dominant tertiary care presences in regional and industrial hubs such as Visakhapatnam, Nellore, Kurnool, Warangal, and Navi Mumbai. The €1.2 billion valuation achieved validates the earnings quality and structural patient demand in tier-2 and tier-3 healthcare ecosystems, areas where public infrastructure remains constrained and private payor density continues to rise.